Skip to main content

Table 2 Input parameters for the Markov model men and women with type 2 diabetes of 60 years or older

From: Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes

Parameters

Men

Women

Distribution

Data source

Detected

Undetected

Detected

Undetected

Incidence

 (100,000 person-years)

658

 

666

 

Fixed

Population estimates 23;24

HF Prevalence

 NYHA I

 

0.007

 

0.000

Dirichlet

Cohort study [5]

 NYHA II

 

0.148

 

0.142

Dirichlet

Cohort study [5]

 NYHA III

 

0.047

 

0.031

Dirichlet

Cohort study [5]

 NYHA IV

 

0.000

 

0.000

Dirichlet

Cohort study [5]

Mortality (year)

0.010

 

0.007

 

Fixed

Population estimates [20]

HF Mortality (year)

 NYHA I

0.042

0.043

0.035

0.036

Fixed

Cohort estimate [5]

 NYHA II

0.066

0.067

0.056

0.057

Fixed

Cohort estimate [5]

 NYHA III

0.103

0.105

0.087

0.089

Fixed

Cohort estimate [5]

 NYHA IV

0.159

0.163

0.137

0.139

Fixed

Cohort estimate [5]

Annual HF costsa

 NYHA I

€1777

€1786

€1172

€1100

Gamma

Cost study [38]

 NYHA II

€2099

€2114

€1370

€1302

Gamma

Cost study [38]

 NYHA III

€3235

€3275

€2070

€2018

Gamma

Cost study [38]

 NYHA IV

€8752

€8912

€5470

€5490

Gamma

Cost study [38]

Medication prescription

 ACE-inhibitors

0.53

0.53

0.27

0.18

 

Cohort study [5]

 Beta-blockers

0.57

0.50

0.50

0.50

 

Cohort study [5]

Utilitiesb

 Diabetes without diagnosed HF

0.868

   

Beta

Cohort study [5]

 NYHA I

0.855

0.817

  

Beta

Cohort study [5]

 NYHA II

0.790

0.739

  

Beta

Cohort study [5]

 NYHA III

0.734

0.685

  

Beta

Cohort study [5]

 NYHA IV

0.665

0.683

  

Beta

Cohort study [5]

  1. aAnnual HF costs were mostly higher for undetected than for detected HF patients. Annual HF costs for detected female HF patients in NYHA class I-III were somewhat higher than for undetected female HF patients in corresponding NYHA classes because of higher use of primary care and medication
  2. bUtilities were assumed to be the same in men and women. Utilities were higher for detected than for undetected HF patients except for NYHA class IV, where utilities were 0.665 and 0.683, respectively